Recipharm’s proprietary molecule Erdosteine has been positively tested as part of COVID-19 treatment
Recipharm is pleased to announce that the results of the study with Erdosteine as an add-on treatment for COVID-19 patients are now available.
The clinical study involved 20 patients affected by COVID-19 with severe respiratory failure, hospitalized in one of the major COVID-19 centres of Milan, in Lombardy, the Italian region mostly affected by SARS-CoV-2.
The study indicates that patients taking Erdosteine after hospital discharge benefit significant improvements in health-related quality of life parameters (HRQoL) and dyspnoea. This study is one of the first to report HRQoL details in patients with COVID-19.
Full study outcomes have been recently published on the peer-reviewed journal Multidisciplinary Respiratory Medicine (Vol. 15, 2020, 713; https://mrmjournal.org/mrm/article/view/713). This study opens up new perspectives for the use of Erdosteine in COVID-19 patients, most likely due to its multiple mechanism of action (antioxidant, mucoactive, anti-inflammatory, antibiotic enhancer) and its ability to increase the endogenous levels of Glutathione. This may have blocked the spreading of the virus in the lungs giving a faster recovery to patients treated.
Erdosteine was discovered and developed in Italy at Recipharm’s facility in Paderno Dugnano and is indicated for the treatment of acute and chronic respiratory diseases including Chronic Obstructive Pulmonary Disease (COPD).
Katherine Salessi Nia, Medical Manager for Erdosteine at Recipharm, commented: ”We have now been able to confirm the beneficial effects of Erdosteine in restoring the pulmonary functions also in patients affected by COVID-19. We are planning to develop further studies to investigate if the molecule can have a role in prophylaxis for this pandemic treatment”.
Carl-Johan Spak, Senior VP Strategic Investments and Projects, email@example.com, +46 8 6025 313
Dr. Katherine Salessi Nia, Medical Manager, firstname.lastname@example.org, +39 0295 0046 282
For media enquiries, please contact Kate Hindhaugh at ramarketing: email@example.com, +44 (0)191 222 1242, ramarketingpr.com, Twitter: @ramarketingpr, Facebook: /ramarketingpr, Linkedin: /ramarketing
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s annual turnover is approximately SEK 11 billion. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.
For more information on Recipharm and our services, please visit www.recipharm.com
Erdosteine is a thiol, discovered in Italy in the Research and Development laboratories of Edmond Pharma, which, thanks to its unique activities, is particularly effective in the treatment of respiratory diseases, such as acute bronchitis, chronic bronchitis and chronic obstructive pulmonary disease. It modulates mucus production and viscosity and increases the motility of the mucociliary transport, improving expectoration. Its clinical efficacy, combined with an excellent safety profile, is proved by more than 3.000 patients treated in 60 clinical trials and by over ten-year experience in clinical practice worldwide.
For more information about Erdosteine, please visit www.erdosteine.net
Recipharm AB (publ)
Corporate identity number 556498-8425
Address Box 603, SE-101 32 Stockholm, Sweden, Telephone +46 8 602 52 00